{"entity":{"id":"idea-fund-conditional-transferable-voucher","kind":"idea","name":"Transferable priority vouchers for first-in-class drugs, with price conditions","aka":[],"tldr":"Reward companies that deliver a genuinely new kind of cancer drug with a sellable voucher for faster review of another product, but only if they agree to fair pricing and global access.","summary":"Extend the US priority review voucher model (rare paediatric disease, tropical disease) to oncology first-in-class approvals that show substantial survival benefit, with two conditions attached: a price commitment (for example launch price below a value-based threshold set by an independent body) and a global access plan (tiered pricing or licensing to the Medicines Patent Pool for low- and middle-income countries). The voucher is transferable and has sold for around $100 million historically, so the reward is real but costs the public little. Regulators would need statutory authority; a pilot could run through an existing programme's criteria.","asOf":"2026-09-08","links":[{"label":"Medicines Patent Pool","url":"https://medicinespatentpool.org/"}],"tags":[],"related":["idea-fund-value-based-patent-extension","idea-fund-global-access-licensing-royalties"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["breakthrough-designation","accelerated-approval"],"trials":[],"people":[],"bottlenecks":["b-incentive-misalignment","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A conditional oncology voucher increases the number of first-in-class oncology approvals meeting the survival threshold per decade and results in launch prices at least 20% lower for voucher-qualified drugs than for comparable unconditioned launches.","rationale":"Rare paediatric vouchers have measurably increased paediatric rare disease activity, though without price conditions; conditional rewards are standard in public procurement. Vouchers reward the outcome (approval) rather than inputs and are cheap for governments.","test":"Model uptake with industry through a regulator-convened consultation, then legislate a five-year sunset pilot and compare first-in-class filings and launch prices before and after.","maturity":"speculative","actor":"regulator","cost":"small","horizonYears":4},"route":"/ideas/idea-fund-conditional-transferable-voucher/","neighbours":{"idea":[{"id":"idea-fund-health-impact-fund-oncology","kind":"idea","name":"A Health Impact Fund pilot that pays for measured health gain instead of price","route":"/ideas/idea-fund-health-impact-fund-oncology/"},{"id":"idea-fund-value-based-patent-extension","kind":"idea","name":"Patent term extension scaled to proven survival gain","route":"/ideas/idea-fund-value-based-patent-extension/"},{"id":"idea-fund-global-access-licensing-royalties","kind":"idea","name":"University licences with royalties indexed to benefit and global access","route":"/ideas/idea-fund-global-access-licensing-royalties/"}],"term":[{"id":"accelerated-approval","kind":"term","name":"Accelerated approval","route":"/terms/accelerated-approval/"},{"id":"breakthrough-designation","kind":"term","name":"Breakthrough Therapy / Priority Review / Priority Voucher","route":"/terms/breakthrough-designation/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}]}}